Ridgefield, Conn. and Indianapolis, June 10, 2019 – Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced detailed findings from the CAROLINA® trial demonstrating that Tradjenta® (linagliptin) did not increase cardiovascular risk compared with glimepiride in adults with type 2 diabetes and cardiovascular risk. The findings were reported today at the American Diabetes Association’s 79th Scientific Sessions® in San Francisco.

The trial met its primary endpoint, defined as non-inferiority for Tradjenta versus glimepiride in time to first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke (3P-MACE), which occurred in 11.8% (356 people) of the Tradjenta group compared with 12.0% (362 people) of the glimepiride group. The overall safety profile of Tradjenta in CAROLINA was consistent with previous data, and no new safety signals were observed.

For more information, click here.